Investor

Welcome to Idenix Pharmaceuticals' Investor Center. The corporate and financial information included in this section of the Web site is intended to assist the investment community in learning more about Idenix and our progress as we advance the discovery and development of drugs for the treatment of human viral and other infectious diseases.
Quicklinks
2010 Annual Report
IDIX (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$5.46
Change (%) Stock is Down 0.04 (0.73%)
Volume710,276
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
RSS
 | More >>
DateTitle 
04/07/14Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C
Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437 Idenix on Track to Initiate All-Oral Pan-Genotypic Phase II Combination Clinical Study of IDX21437 and Samatasvir in mid-2014 Idenix Initiates Phase I Clinical Trial of Follow-on Nucleotide Prodrug, IDX21459 Idenix to Host Conference Call / Webcast at 8:00 a.m. ET today CAMBRIDGE, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical compa... 
Printer Friendly Version
03/24/14Idenix Announces Nucleotide Prodrug (IDX21437) and NS5A Inhibitor (Samatasvir) Poster Presentations at 49th Annual Meeting of the European Association for the Study of the Liver
CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster presentations featuring clinical and preclinical data for the Company's nucleotide prodrug, IDX21437, and for samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, at The International Liver Congress™ 2014, the 49th annual meeting of the Europea... 
Printer Friendly Version
03/24/14Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case
CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it intends to file an appeal to challenge the Oslo, Norway District Court's (the "Court") decision in a patent invalidity case concerning Idenix's co-owned Norwegian patent NO 330 755 that covers certain 2'-methyl-2'-fluoro nucleoside compounds useful in the tr... 
Printer Friendly Version
03/14/14Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe
Granted European Patent Covering 2'-Methyl-2'-Fluoro Nucleosides for Treating Hepatitis C Virus CAMBRIDGE, Mass., March 14, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has filed patent infringement lawsuits against Gilead Sciences, Inc. (Nasdaq:GILD) and/or certain of its subsidiaries in each of three countries - France, German... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

 

 

At Idenix, our corporate values — Innovation, Teamwork, Respect, Quality and Ownership — reflect a unique and dynamic culture.